Sionna’s SION-719 Failure Changes Everything (NASDAQ:SION)
· seekingalpha.com
Sionna Therapeutics (SION) downgraded to Hold after SION-719 Phase 2a failure; cash-rich but pipeline risk rises.
As you already know, Sionna Therapeutics, Inc. ( SION ) announced topline data from its two development programs in cystic fibrosis, and the initial market reac...